ZECUITY Drug Patent Profile

When do Zecuity patents expire, and what generic alternatives are available?

Zecuity is a drug marketed by Teva Branded Pharm and is included in one NDA. There are nine patents protecting this drug.

This drug has ninety-two patent family members in fourteen countries.

The generic ingredient in ZECUITY is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zecuity

A generic version of ZECUITY was approved as sumatriptan succinate by HIKMA on February 6^th, 2009.

Summary for ZECUITY

International Patents:	92
US Patents:	9
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	93
Clinical Trials:	1
Patent Applications:	1,952
DailyMed Link:	ZECUITY at DailyMed

Recent Clinical Trials for ZECUITY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NuPathe Inc.	Phase 1

See all ZECUITY clinical trials

US Patents and Regulatory Information for ZECUITY

ZECUITY is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	7,973,058
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	9,327,114		Y
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	8,470,853
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	8,597,272		Y
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	8,155,737
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	8,366,600

Expired US Patents for ZECUITY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013	6,745,071

International Patents for ZECUITY

See the table below for patents covering ZECUITY around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2526118
Canada	2650412	METHODES ET SYSTEMES TRANSDERMIQUES D'ADMINISTRATION DE COMPOSES ANTI-MIGRAINE (TRANSDERMAL METHODS AND SYSTEMS FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS)
Japan	5951741
Eurasian Patent Organization	025505	СПОСОБ ЛЕЧЕНИЯ МИГРЕНИ У СУБЪЕКТА (METHOD FOR TREATING MIGRAINE IN A SUBJECT)
Australia	2015238858	Pharmacokinetics of iontophoretic sumatriptan administration
New Zealand	596498	Transdermal methods and systems for the delivery of anti-migraine compounds

ZECUITY Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Zecuity?

Zecuity is a transdermal patch delivering sumatriptan, an established treatment for acute migraine. Market adoption has been constrained by safety concerns, competitive landscape, and regulatory responses.

Regulatory and Safety Impact

The U.S. Food and Drug Administration (FDA) issued a safety communication in 2018 due to reports of serious skin reactions, including discoloration, blistering, and necrosis. This led to a black box warning and voluntary recall of Zecuity patches. Since then, sales have declined sharply, limiting its market presence.

Market Size and Competition

The global migraine treatment market was valued at approximately $4.2 billion in 2021 (MarketResearch.com). Sumatriptan tablets, nasal sprays, and newer therapeutic classes like CGRP inhibitors dominate.

Product Class	Market Share (2021)	Notes
Oral Sumatriptan	40%	First-line therapy, widely used
Nasal Spray	25%	Rapid onset, preferred alternative
CGRP Inhibitors	20%	Biologics, newer entrants
Others	15%	Includes transdermal options

Zecuity had a minimal share before the safety issues emerged. Its decline was largely due to safety concerns, not competitive disadvantages.

Pricing and Reimbursement

Before recall, Zecuity was priced around $150–$200 per patch. Insurance coverage was limited, with most payers favoring established alternatives. The safety issues exacerbated reimbursement challenges.

What Is the Financial Trajectory for Zecuity?

Since the recall, Zecuity has exited the market, rendering current revenues and future sales forecast moot.

Historical Revenue Data

Year	Revenue (USD millions)	Notes
2016	20	Launch year, initial sales
2017	15	Market penetration
2018	5	Post-FDA warning, decline
2019	1	Near market exit

Johnson & Johnson, the manufacturer, reported negligible revenues from Zecuity post-2018 and announced it would discontinue sales following the safety concerns.

Development and Recall Costs

Estimates suggest Johnson & Johnson incurred $50–$75 million in costs related to regulatory response, recall logistics, and safety communications. These costs impacted overall financial performance, especially within the neurology portfolio.

Future Outlook

No planned relaunch exists. The primary pathway involves reformulation or new safety data, which seems unlikely given current safety profile issues. As a result, Zecuity is effectively off the radar for future revenue.

How Do Regulatory Pathways Affect Future Potential?

Regulatory agencies globally prioritize safety. The current safety concerns make launching a reformulated Zecuity challenging.

FDA Recommendations

• Limitations on similar transdermal devices for migraine without extensive safety data.
• Emphasis on alternative delivery systems with better safety profiles.

Potential for Resubmission

Reintroduction would require:

• Comprehensive safety data from new clinical trials.
• Demonstration of risk mitigation strategies.
• Likely a lengthy and costly process exceeding $100 million.

Given these hurdles, revitalizing Zecuity appears unlikely unless a significant breakthrough occurs in addressing skin reactions.

What Are the Strategic Implications?

Investors and companies should note:

• The market for migraine treatments is mature, with established players.
• Safety issues can derail product pipelines, especially for delivery devices.
• Resources may be better allocated to emerging therapies or safer formulations.

Key Takeaways

• Zecuity faced safety issues leading to a market exit and significant financial loss.
• The global migraine market remains highly competitive, dominated by oral and biologic options.
• Future prospects for Zecuity depend on overcoming safety hurdles, which is unlikely without major reformulation.
• Its decline illustrates the critical importance of safety data in drug and device markets.
• No plans for relaunch or reformulation publicly announced.

FAQs

1. Can Zecuity be reintroduced to the market?
It is unlikely without extensive reformulation and new safety data, which would require significant investment and regulatory approval.

2. Are there similar transdermal migraine treatments available?
Yes, products like Estabbio (frovatriptan transdermal system) and self-adhesive patches in development exist, but none match Zecuity's market presence.

3. How did safety concerns impact Johnson & Johnson’s neurology portfolio?
The safety issues with Zecuity contributed to reputational risk and financial costs, but the broader portfolio focuses on biologics and small molecules with established safety profiles.

4. What regulatory lessons can be learned from Zecuity?
Pre-market safety assessment must thoroughly evaluate dermatological and systemic reactions, especially for transdermal systems.

5. What are the prospects for new migraine delivery devices?
Innovation continues, but safety and efficacy remain the primary considerations. The market favors proven, well-tolerated options.

---

Citations
[1] MarketResearch.com. "Migraine Treatment Market Size & Trends," 2021.